TY - JOUR AU - J., Vidal AU - B., Bellosillo AU - C., Santos Vivas AU - P., Garcia-Alfonso AU - A., Carrato AU - M.T., Cano AU - R., Garcia-Carbonero AU - E., Elez AU - F., Losa AU - B., Massuti AU - Valladares Ayerbes, Manuel AU - J.M., Vieitez AU - J.L., Manzano AU - D., Azuara AU - J., Gallego AU - S., Pairet AU - G., Capella AU - R., Salazar AU - J., Tabernero AU - E., Aranda AU - C., Montagut PY - 2019 SN - 0923-7534 UR - http://hdl.handle.net/20.500.11940/16061 AB - BACKGROUND: Extended RAS analysis is mandatory in metastatic colorectal cancer (mCRC) patients. The optimal threshold of RAS mutated subclones to identify patients most likely to benefit from antiepidermal growth factor receptor (EGFR) therapy is... LA - eng KW - Membrane Proteins KW - Adult KW - Proto-Oncogene Proteins B-raf KW - Middle Aged KW - Neoplasm Metastasis KW - GTP Phosphohydrolases KW - Protein Kinase Inhibitors KW - Proto-Oncogene Proteins p21(ras) KW - Antineoplastic Combined Chemotherapy Protocols KW - Mutation KW - Class I Phosphatidylinositol 3-Kinases KW - DNA Mutational Analysis KW - Humans KW - Treatment Outcome KW - Disease-Free Survival KW - High-Throughput Nucleotide Sequencing KW - Colorectal Neoplasms TI - Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy DO - 10.1093/annonc/mdz005 T2 - ANNALS OF ONCOLOGY M2 - 439 KW - CHUAC VL - 30 ER -